



Investor Presentation

November 2023



Disclaimer

The information contained in this document ("Document") has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as "Alcidion" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Alcidion periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein. The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast.

The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Alcidion's business and markets. Such information is generally based on independent market and industry data or research. The Alcidion has not independently verified, and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Financial data

All financial amounts contained in this presentation are expressed in Australian dollars (unless otherwise stated). Any discrepancies between totals and sums of components in tables, figures and body content contained in this presentation are due to rounding. Tables, figures and body content contained in this presentation have not been amended by ALC to correct immaterial summation differences that may arise from this rounding convention.

Investors should also be aware that certain financial data included in this presentation including underlying NPAT and underlying EBIT/EBITDA and measures described as "pro-forma", are "non-IFRS financial information" under ASIC regulatory Guide 230 (disclosing non-IFRS financial information). The non-IFRS financial information financial measures do not have a standardised meaning prescribed by Australian International Reporting Standards (AIFRS) and, therefore, may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other measures determined in accordance with AIFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial measures included in this presentation.

Alcidion helps healthcare organisations harness the power of technology to create a clinically relevant environment with digitally enabled care...


“Making the right thing to do, the easiest thing to do”



Alcidion – a snapshot

- Healthcare software and informatics company providing an innovative technology platform to improve the **efficiency and quality of patient care**
- Aggregate and analyse data, using AI to enable a **proactive** (rather than reactive) approach to patient care
- 400+ hospitals across 95 healthcare organizations using our solutions – strong, referenceable customer base
- Flagship platform, **Miya Precision** deploys in a modular approach accommodating customer priorities & budgets
- Strong technical services capability (integration, consultancy, training) complements our software products
- FY23 (30 June Y/E) revenue of **\$40.4M**, with **70%+ recurring revenue**
- Gross profit margins of **85%+**; **forecasting operating cash flow positive for FY24**
- Founders and management **own ~20%**

Challenges facing healthcare providers



- Ageing population
- Rise in chronic disease
- Virtual Care (out of hospital)

- Resource availability
- Clinical productivity
- Budget pressure

- Increasing penalties for unsafe care and poor outcomes

Healthcare providers must adopt technology to improve patient outcomes and deliver efficiencies to meet demand

Healthcare needs to further extend digital capabilities to increase automation and reduce administrative burden

US\$1TR

Cost of preventable errors per annum, globally

1 in 4

Australian patients who stay overnight will develop a hospital-acquired complication

>\$4.1B

Cost to the Australian public sector of hospital-acquired complications

3rd

Adverse events in hospital are 3rd leading cause of death in the US

Smarter Solutions for Clinicians



Powering Smarter Care

At the core of Alcidion's solutions is our FHIR-based interoperability platform for smarter decision support

Miya Precision Platform



Data to FHIR,
Ontology Mapping,
CDS Engine



Patient Flow

Industry leading digital patient flow journey boards



Virtual Care

Virtual care and remote patient management



Operations Centre

Integrated Operations Centre enablement



Specialised Care

Emergency Department and Specialised Care



Data & Analytics

Real-time data replication, insights and predictive analytics



Integrated Care Record

Longitudinal patient health record



Modern Modular EPR

Modular cloud-native EPR and PAS




Clinical Enablement


NLP enabled noting, assistive workflow tasking, clinical comms, and mobility

Miya Precision – leveraging AI and NLP¹

- Using AI and deeply embedded NLP Miya Precision enables clinical risk detection
- Flexible Clinical Decision Support (CDS) such as...
 - Use CDS to monitor patients in the home for deterioration (remote or virtual care)
 - Identify critical results and notify care giver to act
 - Automate the process of detection of challenging complications like hypoglycemia




Patient Details	Note	MyaCare	Tasks	Type	Referrals	Medications	Comorb.	Symptoms	Recent Labs	Care Protocols	Detected Issue	Meetings	Patient Tasks	Follow-up	BGL
Anthony, Lyra NHI 9608771 69y			<ul style="list-style-type: none"> Please call the patient later ... Review BP (abnormal) Review medications 	Type 2	CARD	Insulin	1	Headache		Diet, DM	20% increase in HbA1C	Today	<ul style="list-style-type: none"> 1 Overdue 1/2 Completed 	Overdue	7.5 mmol/L @ 23:30 28 Jun 23
Byrd, Benson NHI 9977666 55y			<ul style="list-style-type: none"> Medication Review 	Type 2	PHAR	Metfor...	1						<ul style="list-style-type: none"> 1 Overdue 0/1 Completed 		6.7 mmol/L @ 23:30 28 Jun 23
Dunn, Romina NHI 6481602 50y			<ul style="list-style-type: none"> Abnormal Temp: 38.1C Wound Care 	Type 1	PHAR	Insulin	No Sig.	Temp > 38					<ul style="list-style-type: none"> 1 Overdue 1/2 Completed 		7.8 mmol/L @ 23:30 28 Jun 23
Ferguson, Jett NHI 7406821 95y			<ul style="list-style-type: none"> Fasting Blood Sugar Test 	Type 2	OT	Metfor...	2						<ul style="list-style-type: none"> 2 Overdue 0/2 Completed 		6 mmol/L @ 23:30 28 Jun 23
Guthrie, Cannon NHI 8836163 76y			<ul style="list-style-type: none"> Diabetes Educator Review Pressure Care 	Type 2	DNS DIET	Amylin	2	Headache					<ul style="list-style-type: none"> 1 Overdue 1/2 Completed 	Overdue	7.9 mmol/L @ 23:30 28 Jun 23
Hayden, Sam NHI 9039363 45y			<ul style="list-style-type: none"> Medication Review Pain Rating - 9 Unable to drink 	Type 1	CARD PHAR	Amylin Glitazone	3	Mod SOB Temp > 38					<ul style="list-style-type: none"> 2 Overdue 0/2 Completed 		6.1 mmol/L @ 23:30 28 Jun 23
Mann, Logan NHI 1695784 83y			<ul style="list-style-type: none"> Medication review 	Type 2	DIET	Insulin	1	URTI Symp...		Diet, DM			<ul style="list-style-type: none"> 2 Overdue 0/2 Completed 		8 mmol/L @ 13:54 11 Jul 23
May, Nicolas NHI 4876862 83y			<ul style="list-style-type: none"> Review Kidney Function 	Type 2	UROLOG	Metfor...	1			DM			<ul style="list-style-type: none"> 1 Overdue 0/1 Completed 		6.9 mmol/L @ 23:30 28 Jun 23
Mcgee, Monica NHI 6394991 71y			<ul style="list-style-type: none"> Medical Review Diabetes Educator Review 	Type 1	UROLOG DNS	Insulin	No Sig.			Diet, DM	10% increase in HbA1C		<ul style="list-style-type: none"> 2 Overdue 0/2 Completed 		7.2 mmol/L @ 23:30 28 Jun 23



Miya Precision...making it easier for clinicians

- **Device Agnostic** – new generation of clinicians comfortable using mobile/tablet
- **Intuitive dashboards** – easy to read while time poor and on the move
- **Clinical support** – assisting clinicians with relevant tests and workflows given the patients presenting symptoms – identifying risks
- **Predictive analytics** - insightful patient health data is continuously monitored, analysed and interrogated for better decision making
- **Real-time alerts** - Changes in the patient condition empower early intervention



Flagship customers validating Alcidion offering...

Customers are very 'sticky' with average contact length of **3-5 years** with further options to extend; **critical enterprise health software**



- **US\$21M¹ TCV²** for Alcidion over 5.5 years
 - TCV for Leidos of US\$221M
- Further option to extend **up to 15 years**
- Delivering Health Knowledge Management system across the Australian Defence Force
- Alcidion providing Longitudinal Health Record, aggregating data from systems



South Tees Hospitals
NHS Foundation Trust



South Tees NHS Trust (UK)

- **US\$7.6M** over 5 years
- Full clinical suite of Miya Precision platform
- Key reference site for Miya Precision in UK market
- Provides framework for broader EPR capability and ICS convergence



Northern Territory Health (Australia)

- 14-year relationship
- Recently, upgraded from early version of Miya to current Miya Precision platform
- State-wide contract and validates breadth of functionality of Miya platform
- Integrated with existing EMR



Salford Care Organisation
Northern Care Alliance NHS Group



Salford Care NHS (UK)

- Alcidion providing patient flow mgmt. as part of £25m large-scale IT project with lead contractor, Hitachi Consulting
- UK's 1st 'Digital Control Centre'; integrated digital transformation of care processes
- Access to valuable IP to evolve Miya Precision for Digital Command Centre

1. USD @.67 AUD
2. Total Contact Value

FY23 – Financial Highlights


Continuing to build scale through increased recurring revenue supported by positive operating cashflow

Revenue \$40.4M ↑ 18% ¹	Recurring Revenue \$28.1M ↑ 21%
Gross Margin 86.1% ↑ 0.3pts	Sold Revenue For FY24² \$33.7M ↑ 8%
EBITDA (\$1.5M) ↑ \$0.1M	FY23 TCV³ new sales \$29.9M ↓ 48%
Operating Cashflow \$0.2M ↓ \$0.8M	Cash (30 June 2023) \$14.6M ↓ \$2.7M

1. Comparisons are to prior corresponding period (FY22)
 2. Includes both contracted and scheduled renewals
 3. Total Contract Value

Global expansion potential...

Current Operations



Future Geographical Expansion

Key Criteria:

- Sizable market
- English speaking (reduced development spend)
- Healthcare structure similar to UK / Australia
- Access to digital healthcare data

Target location:

- North America (initial focus on Canada)
- Europe – Nordics priority
- United Arab Emirates (UAE)
- Southeast Asia

Investment Highlights

Large Addressable Market

- 146 Acute UK NHS Trusts; ALC with foothold in only approximately 27%
- Focus on management of patients efficiently sees increasing opportunity in ANZ
- AUS opportunity in private hospital and virtual care setting
- Geographical expansion on radar

Product Offering

- Cloud native, modern modular platform improving hospital efficiencies and clinical decision-making
- Highly interoperable and built on open standards
- Designed to be an active participant in health care rather than passive data store

Strong Financial Profile

- ~70% recurring revenue, supported by multi-year contracts
- Gross profit margins > 85%
- Forecasting operating cashflow positive for FY24
- \$33.7M contracted revenue in FY24

Long-term Contracts


- Long-term customer contracts (3-5 years) with ongoing options for renewal
- Critical nature of software results in negligible churn
- Enterprise healthcare organisations (NHS Trusts, State health, private health)

Marquee Customers

- \$31.7M over 5.5 years with Leidos (Aus) to assist Australian Defence Force with health record
- \$11.3M over 5 years with South Tees NHS (UK) for full Miya Precision suite
- NT Health, Qld Health (Aust. state health organisations) + other large NHS Trusts

Market Tailwinds

- Health systems stretched with limited bed availability & under-resourced clinical staff seeking improved tech solutions for efficiency
- UK Government remaining committed to their pursuit of modernising the NHS, significant funding being allocated



ALCIDION